Does the media refer more to IPSC or IMCR?

In the previous week, Immunocore had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Immunocore and 3 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.00 beat Immunocore's score of -0.14 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IPSC or SEPN?

In the previous week, Septerna had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Septerna and 3 mentions for Century Therapeutics. Septerna's average media sentiment score of 0.42 beat Century Therapeutics' score of 0.00 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IPSC or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% ArriVent BioPharma N/A -48.98% -45.44%

Does the media refer more to IPSC or AVBP?

In the previous week, Century Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for ArriVent BioPharma. Century Therapeutics' average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MPLT or IPSC more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Century Therapeutics N/A -49.89% -37.42%

Does the media favor MPLT or IPSC?

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 3 articles in the media. Maplight Therapeutics' average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IPSC or XERS?

In the previous week, Xeris Biopharma had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Xeris Biopharma and 3 mentions for Century Therapeutics. Xeris Biopharma's average media sentiment score of 0.15 beat Century Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Century Therapeutics (IPSC) Competitors

$2.25 -0.06 (-2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 +0.00 (+0.22%)

As of 04:10 PM Eastern

Compare

IPSC vs. IMCR, SEPN, AVBP, MPLT, and XERS

Should you buy Century Therapeutics stock or one of its competitors? MarketBeat compares Century Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Century Therapeutics include Immunocore (IMCR), Septerna (SEPN), ArriVent BioPharma (AVBP), Maplight Therapeutics (MPLT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Century Therapeutics compare to Immunocore?

Century Therapeutics (NASDAQ:IPSC) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Century Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Immunocore	-6.68%	-7.07%	-2.55%

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Century Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Century Therapeutics has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.72	-$9.58M	-$1.14	N/A
Immunocore	$400.02M	4.06	-$35.51M	-$0.55	N/A

In the previous week, Immunocore had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Immunocore and 3 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.00 beat Immunocore's score of -0.14 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics presently has a consensus target price of $4.75, suggesting a potential upside of 111.11%. Immunocore has a consensus target price of $56.71, suggesting a potential upside of 77.51%. Given Century Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Immunocore	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Immunocore beats Century Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Septerna?

Century Therapeutics (NASDAQ:IPSC) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Century Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Septerna	-49.88%	-12.72%	-8.87%

50.2% of Century Therapeutics shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Comparatively, 5.8% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Century Therapeutics has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.72	-$9.58M	-$1.14	N/A
Septerna	$45.95M	35.25	-$48.88M	-$0.81	N/A

In the previous week, Septerna had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Septerna and 3 mentions for Century Therapeutics. Septerna's average media sentiment score of 0.42 beat Century Therapeutics' score of 0.00 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics currently has a consensus price target of $4.75, indicating a potential upside of 111.11%. Septerna has a consensus price target of $45.89, indicating a potential upside of 27.72%. Given Century Therapeutics' higher possible upside, research analysts clearly believe Century Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Century Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

Summary

Septerna beats Century Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Century Therapeutics compare to ArriVent BioPharma?

Century Therapeutics (NASDAQ:IPSC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Century Therapeutics presently has a consensus price target of $4.75, suggesting a potential upside of 111.11%. ArriVent BioPharma has a consensus price target of $44.83, suggesting a potential upside of 33.08%. Given Century Therapeutics' higher probable upside, equities analysts plainly believe Century Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Century Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for ArriVent BioPharma. Century Therapeutics' average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Century Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Century Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.72	-$9.58M	-$1.14	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma's return on equity of -48.98% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

Century Therapeutics beats ArriVent BioPharma on 9 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Century Therapeutics (NASDAQ:IPSC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

50.2% of Century Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Maplight Therapeutics currently has a consensus target price of $39.10, suggesting a potential downside of 0.56%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 111.11%. Given Century Therapeutics' higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than Maplight Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Century Therapeutics	$109.16M	3.72	-$9.58M	-$1.14	N/A

Maplight Therapeutics' return on equity of 0.00% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Century Therapeutics	N/A	-49.89%	-37.42%

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 3 articles in the media. Maplight Therapeutics' average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Maplight Therapeutics beats Century Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Century Therapeutics compare to Xeris Biopharma?

Century Therapeutics (NASDAQ:IPSC) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Xeris Biopharma had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Xeris Biopharma and 3 mentions for Century Therapeutics. Xeris Biopharma's average media sentiment score of 0.15 beat Century Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.72	-$9.58M	-$1.14	N/A
Xeris Biopharma	$291.85M	4.93	$550K	$0.06	139.00

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Century Therapeutics presently has a consensus price target of $4.75, suggesting a potential upside of 111.11%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 29.50%. Given Century Therapeutics' higher possible upside, equities analysts clearly believe Century Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has a net margin of 3.81% compared to Century Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Xeris Biopharma	3.81%	735.00%	3.24%

Century Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Summary

Xeris Biopharma beats Century Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$405.79M	$3.04B	$6.83B	$12.61B
Dividend Yield	N/A	2.08%	2.68%	7.79%
P/E Ratio	-1.97	19.75	27.27	24.57
Price / Sales	3.72	488.46	546.85	110.43
Price / Cash	182.71	57.49	48.45	59.17
Price / Book	1.24	4.30	10.91	6.39
Net Income	-$9.58M	$64.32M	$3.57B	$331.53M
7 Day Performance	-7.41%	-0.73%	-0.22%	0.32%
1 Month Performance	6.13%	6.66%	5.79%	2.16%
1 Year Performance	263.96%	22.49%	28.25%	20.99%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	1.3954 of 5 stars	$2.25 -2.6%	$4.75 +111.1%	+269.2%	$405.79M	$109.16M	N/A	170	News Coverage Gap Down
IMCR Immunocore	2.9176 of 5 stars	$32.72 +2.4%	$56.71 +73.4%	-4.3%	$1.66B	$400.02M	N/A	320	News Coverage Analyst Downgrade
SEPN Septerna	2.4928 of 5 stars	$36.38 +8.7%	$45.89 +26.1%	+222.9%	$1.64B	$45.95M	N/A	N/A
AVBP ArriVent BioPharma	1.6917 of 5 stars	$34.40 -0.3%	$43.14 +25.4%	+57.8%	$1.60B	N/A	N/A	40
MPLT Maplight Therapeutics	1.2903 of 5 stars	$36.99 +5.6%	$38.80 +4.9%	N/A	$1.58B	N/A	N/A	109	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 7/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. IMCR, SEPN, AVBP, MPLT, and XERS

How does Century Therapeutics compare to Immunocore?

Summary

How does Century Therapeutics compare to Septerna?

Summary

How does Century Therapeutics compare to ArriVent BioPharma?

Summary

How does Century Therapeutics compare to Maplight Therapeutics?

Summary

How does Century Therapeutics compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. IMCR, SEPN, AVBP, MPLT, and XERS

How does Century Therapeutics compare to Immunocore?

Is IPSC or IMCR more profitable?

Do insiders and institutionals hold more shares of IPSC or IMCR?

Which has more risk & volatility, IPSC or IMCR?

Which has better earnings & valuation, IPSC or IMCR?

Does the media refer more to IPSC or IMCR?

Do analysts rate IPSC or IMCR?

Summary

How does Century Therapeutics compare to Septerna?

Is IPSC or SEPN more profitable?

Do institutionals and insiders believe in IPSC or SEPN?

Which has better valuation and earnings, IPSC or SEPN?

Does the media favor IPSC or SEPN?

Do analysts rate IPSC or SEPN?

Which has more risk and volatility, IPSC or SEPN?

Summary

How does Century Therapeutics compare to ArriVent BioPharma?

Do analysts prefer IPSC or AVBP?

Does the media refer more to IPSC or AVBP?

Do institutionals & insiders hold more shares of IPSC or AVBP?

Which has more risk and volatility, IPSC or AVBP?

Which has stronger valuation & earnings, IPSC or AVBP?

Is IPSC or AVBP more profitable?

Summary

How does Century Therapeutics compare to Maplight Therapeutics?

Do institutionals and insiders hold more shares of MPLT or IPSC?

Do analysts prefer MPLT or IPSC?

Which has better earnings and valuation, MPLT or IPSC?

Is MPLT or IPSC more profitable?

Does the media favor MPLT or IPSC?

Summary

How does Century Therapeutics compare to Xeris Biopharma?

Does the media favor IPSC or XERS?

Which has better valuation & earnings, IPSC or XERS?

Do insiders and institutionals have more ownership in IPSC or XERS?

Do analysts recommend IPSC or XERS?

Is IPSC or XERS more profitable?

Which has more volatility and risk, IPSC or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools